Results 21 to 30 of about 26,051 (185)
Biomedicines, 2022 Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen +3 more
doaj +1 more source
A case of cardiac amyloidosis incidentally detected by bone scintigraphy [PDF]
Asia Oceania Journal of Nuclear Medicine and Biology, 2021 A 73-year-old man with lung cancer underwent bone scintigraphy for disease staging. Diffuse myocardial technetium hydroxymethylene diphosphonate (99mTc-HMDP) uptake was incidentally found.
Hiroki Tanaka +7 more
doaj +1 more source
Annals of Internal Medicine, 2023 Amyloidosis is a pathologic and clinical condition resulting from the accumulation of insoluble aggregates of misfolded proteins in tissues. Extracellular deposition of amyloid fibrils in the myocardium leads to cardiac amyloidosis, which is often overlooked as a cause of diastolic heart failure.
Michelle Weisfelner Bloom +1 more
openaire +4 more sources
Role of cardiac MRI in the diagnosis of cardiac amyloidosis. Clinical cases
Клинический разбор в общей медицине, 2021 Purpose. The aim of this work is to show the capabilities of late gadolinium enhancement cardiac magnetic resonance imaging (MRI) in the diagnosis of a rare disease such as cardiac amyloidosis. Materials and methods.
Ekaterina A. Butorova +1 more
doaj +1 more source
Clinical Medicine, 2005 Systemic amyloidosis commonly affects the heart. Indeed, cardiac symptoms may be the first clinical indicator of underlying amyloid deposition. Using two case studies, this article reviews the latest evidence regarding cardiac amyloidosis. The diagnosis of cardiac involvement can be established through imaging with echocardiography and magnetic ...
Maredia, Neil, Ray, Simon G
openaire +2 more sources
Methodist DeBakey Cardiovascular Journal, 2022 Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications. However, the last decade has seen significant advances in disease-modifying therapies, increased awareness of CA, and improved
Lily K. Stern, Jignesh Patel
openaire +3 more sources
Transthyretin cardiac amyloidosis
Cardiovascular Research, 2022 AbstractTransthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a
Aldostefano Porcari +2 more
openaire +4 more sources
Transthyretin cardiac amyloidosis.
Medicine and pharmacy reports, 2021 Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality if untreated.
Tomoaia, Raluca +6 more
openaire +2 more sources
Cardiac Care of Patients with Cardiac Amyloidosis [PDF]
Acta Haematologica, 2020 Cardiac amyloidosis, the majority of cases of which are due to immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), affects different aspects of the heart and cardiovascular system. Amyloid-induced cardiomyopathy, clinically manifesting with heart failure and electrophysiological abnormalities, has distinct characteristics ...
Osnat, Itzhaki Ben Zadok, Ran, Kornowski
openaire +2 more sources
Catastrophic Cardiac Amyloidosis [PDF]
Cardiology Research and Practice, 2011 We report a case of a 61-year-old patient presenting with cardiogenic shock. His echocardiogram suggested typical features of cardiac amyloidosis. This case demonstrates that cardiac amyloidosis can present acutely and may be catastrophic.
Prashanth Panduranga, Mohammed Mukhaini
openaire +3 more sources